References
Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Holm Damgaard L, Buchholtz K, Skalshøi Kjær M, Balendran C, Myers RP, Loomba R, Noureddin M (2022) Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol. https://doi.org/10.1016/j.jhep.2022.04.003
Polyzos SA, Kountouras J, Zavos C, Deretzi G (2012) Nonalcoholic fatty liver disease: Multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 46:272–284
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP (2012) Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. Expert Opin Pharmacother 13:287–288
Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113–1124
Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M (2020) Cilofexor, a Nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a Phase 2 Randomized Controlled Trial. Hepatology 72:58–71
Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, Bhandari BR, Gunn N, Caldwell SH, Goodman Z, Wapinski I, Resnick M, Beck AH, Ding D, Jia C, Chuang JC, Huss RS, Chung C, Subramanian GM, Myers RP, Patel K, Borg BB, Ghalib R, Kabler H, Poulos J, Younes Z, Elkhashab M, Hassanein T, Iyer R, Ruane P, Shiffman ML, Strasser S, Wong VW, Alkhouri N (2021) Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology 73:625–643
Polyzos SA, Kang ES, Boutari C, Rhee EJ, Mantzoros CS (2020) Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 111S:154203
Polyzos SA, Kechagias S, Tsochatzis E (2021) Review article: non-alcoholic fatty liver disease and cardiovascular diseases - associations and treatment considerations. Aliment Pharmacol Ther 54:1013–1055
Lawitz EJ, Bhandari BR, Ruane PJ, Kohli A, Harting E, Ding D, Chuang JC, Huss RS, Chung C, Myers RP, Loomba R (2022) Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with Cilofexor/Firsocostat. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2021.12.044
Author information
Authors and Affiliations
Contributions
SAP: Conception and design, review of the literature, acquisition of articles, interpretation of articles, drafting the article and revising it critically for important intellectual content, and final approval of the version to be submitted.
NK: Conception and design, review of the literature, acquisition of articles, interpretation of articles, drafting the article and revising it critically for important intellectual content, and final approval of the version to be submitted.
Both authors ensure that the article is original work, has not been previously published, and is not under consideration for publication elsewhere.
Corresponding author
Ethics declarations
Conflict of interest
SAP has no conflict of interest.
NK has given talks, attended conferences and participated in trials sponsored by Amgen, Astra Zeneca, Bausch Health, Boehringer Ingelheim, Elpen, Novartis, Novo Nordisk, Sanofi, Servier, Viatris, Vianex, and WinMedica.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Polyzos, S.A., Katsiki, N. Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer. Hormones 21, 513–514 (2022). https://doi.org/10.1007/s42000-022-00379-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s42000-022-00379-6